Although in that study these observations were associated with marked hypertension, which was mitigated by CXCR4 antagonism, the current study demonstrates that the anti-fibrotic effects of CXCR4 antagonism are not blood pressure dependent. The gene discussed is CXCR4; the disease is Hypertension.